Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis
| Autor: | Qing-qun Cai, Kun-hai Zhuang, Xinlin Chen, Hui-biao Li, Hong-mei Tang, Mu-yuan Chen, Zhen-wen Qiu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Aminosalicylic acid Cochrane Library law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans 030212 general & internal medicine Adverse effect Randomized Controlled Trials as Topic ulcerative colitis medicine.diagnostic_test business.industry Probiotics General Medicine Aminosalicylic Acid Combined Modality Therapy meta-analysis Clinical trial Treatment Outcome chemistry 030220 oncology & carcinogenesis Meta-analysis Relative risk Erythrocyte sedimentation rate bifid triple viable Colitis Ulcerative business Systematic Review and Meta-Analysis Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Objective: Ulcerative colitis (UC), one of the most stubborn diseases, is mainly treated by aminosalicylic acid (ASA). However, the side effects of ASA include vomiting, nausea, rash, diarrhea, headache, etc, which seriously affect life-quality of UC patients. Probiotics such as bifid triple viable (BTV) could reduce drug-induced adverse reactions and has a good clinical effect on UC. Therefore, we aimed to evaluate the clinical efficacy and safety of BTV plus ASA in treating UC. Methods: PubMed, Cochrane Library, Embase, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, Chinese National Knowledge Infrastructure, and Wanfang databases were searched from the inception dates to October 12, 2018. Randomized controlled trials (RCTs) were included by comparing BTV plus ASA programs with ASA alone in patients with UC. Methodological quality was assessed by 2 independent researchers according to the inclusion criteria and exclusion criteria. Meta-analysis was performed by using the Review Manager 5.3 Software. Risk ratios (RRs), 95% confidence interval (CI), and standardized mean difference were calculated. Results: Sixty RCTs involving 4954 participants were selected for final review. Compared with ASA, BTV plus ASA significantly improved the clinical effect rate [RR = 1.23, 95% CI (1.20, 1.26), P < .00001]; reduced the relapse rate [RR = 0.34, 95% CI (0.18, 0.62), P = .0005]; and adverse effect rate [RR = 0.66, 95% CI (0.53, 0.82), P = .0002]. Compared with the controls, levels of tumor necrosis factor-α, interleukin-6 (IL-6), IL-8, C-reactive protein (CRP), hypersensitive CRP, erythrocyte sedimentation rate, and malondialdehyde were reduced; levels of IL-10, CD3+, CD4+, and superoxide dismutase were increased in BTV plus ASA group. Conclusions: BTV plus ASA has positive therapeutic effects on UC, and it might be a safe way to treat UC. However, comprehensive clinical trials are needed to obtain high level of clinical evidence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|